• About Us
  • Add Post
  • Contact
  • Contribute For Us
  • Homepage
  • Our Authors
  • Privacy Policy
Facebook Twitter Instagram
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors
Facebook Twitter LinkedIn
BusinessLendBusinessLend
  • NEWS
  • BUSINESS
  • AUTO
  • TECH
  • MONEY
  • STARTUP
  • SUCCESS STORIES
  • OTHER
    • Press Release
    • OPINION
Subscribe
BusinessLendBusinessLend
Press Release

BioMatrix Specialty Pharmacy Welcomes Kathee Kramm to Executive Team

PR NewsWireBy PR NewsWireMay 17, 2023No Comments3 Mins Read

Kramm Appointed as President and Chief Operating Officer

PLANTATION, Fla., May 16, 2023 /PRNewswire/ — BioMatrix Specialty Pharmacy announced today Kathee Kramm has joined the executive leadership team as President and Chief Operating Officer. Working in collaboration with the CEO and CFO, Kathee will oversee sales, operations, nursing and revenue cycle management. She will play an integral role in BioMatrix’s strategic priorities as a leader in the specialty infusion pharmacy industry.

Kathee Kramm appointed as BioMatrix Specialty Pharmacy President & Chief Operating Officer

Tweet this

Kathee Kramm, President & COO, BioMatrix Specialty Pharmacy
Kathee Kramm, President & COO, BioMatrix Specialty Pharmacy

Ms. Kramm is an accomplished, entrepreneurial healthcare executive extensively experienced in specialty pharmacy and home infusion. She has successfully designed and implemented growth strategies for several industry-leading infusion, specialty, and mail order pharmacies. Kathee has also successfully transitioned businesses through multiple private equity recapitalizations and participated in sale negotiations and integration efforts. 

Most recently, Kathee served as President and Co-Founder of AxelaCare Health Solutions (now Optum Infusion), where her key areas of focus included operations, building national sales teams, nursing networks, and payer alliances to improve care and therapy access for patients with rare and chronic health conditions. Prior to AxelaCare, Kathee was a co-founder of Home Patient Care which eventually was sold to Amerisource Bergen and rebranded as US BioServices.

“We are excited to partner with Kathee and welcome her to our executive leadership team,” CEO Nick Karalis affirms. “Kathee’s background, experience, and leadership will further enhance BioMatrix’s investment and focus on specialty infusion, bleeding disorders, 340b and HUB/ LDD services. Her skill set combined with her enthusiasm and entrepreneurial spirit makes her a perfect addition to the team.”

Kathee Kramm shares, “I am impressed with and motivated by the staff and the resources BioMatrix possesses. The wealth of industry experience, resources, and passion BioMatrix has in prioritizing patient care above all else is unique in the specialty infusion pharmacy space. I am elated to be a part of the BioMatrix family and look forward to playing a role in the continued growth of the organization.”

For more information on BioMatrix Specialty Pharmacy, please visit www.biomatrixsprx.com.

About BioMatrix Specialty Pharmacy
BioMatrix Specialty Pharmacy, an Inc. 5000 company, offers comprehensive, nationwide specialty infusion pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our commitment to every patient is to provide individualized pharmacy services, timely access to care, and focused education and support. We offer a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

Media Contact
Tara Marchese, Senior Director of Marketing – BioMatrix Specialty Pharmacy
P:  954-908-7636
E:  [email protected] 

SOURCE BioMatrix Specialty Pharmacy

PR NewsWire

PR Newswire is a distributor of press releases headquartered in Chicago. The service was created in 1954 to allow companies to electronically send press releases to news organizations, using teleprinters at first. The founder, Herbert Muschel, operated the service from his house in Manhattan for approximately 15 years.

Related Posts

OnlyFans Search Unveiled: Fanscout’s Groundbreaking New Approach

December 10, 2023

Die Menarini Group präsentiert auf dem SABCS 2023 neue progressionsfreie Überlebensdaten aus der klinischen EMERALD-Studie zu ORSERDU® (Elacestrant) in klinisch relevanten Untergruppen von Patienten mit ER+, HER2- metastasiertem Brustkrebs (Metastatic Breast Cancer, mBC) mit ESR1-Mutationen USA – Deutsch USA – English USA – English Latin America – español USA – Italiano

December 10, 2023
Add A Comment

Comments are closed.

© 2023 BusinessLend. Designed by ThemeSphere.
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors

Type above and press Enter to search. Press Esc to cancel.